Pierre Fabre and MHB collaborate on plant projects
with Canadian bioresearcher Millenia Hope Biopharma (MHB), which
may yield new plant-based products for use by the nutraceuticals
industry.
The companies have called their collaboration "important", but a spokesperson for Pierre Fabre was unable to revealed details about how exactly it will work due to a confidentiality agreement.
Nonetheless, a collaboration between the two organisations, both of which have impressive resources for the exploitation and commercialisation of plant for health and cosmetic uses, could help expand the plant-based toolkit that nutraceutical industry has at its disposal when designing health enriching products.
Pierre Fabre, located in Castries, focuses on the development of plant-derived health, ethical and dermo-cosmetic products. Its efforts in the field of oncology account for 50 per cent of its R&D spend, with the remainder devoted to the central nervous system, cardiology, internal medicine/urology, and dermatology.
MHB, meanwhile, has devoted more than US$25m to developing its Phytomics Technologies, which includes a collection of purified phytochemical fractions for use by the nutraceutical, pharmaceutical and cosmetics industries.
MHB said that it is in the midst of commercialising several projects with leading multinational corporations.
